Who is sponsoring NCT00904488?

NCT00904488 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT00904488?

Interventions in NCT00904488: Addition of oral Metolazone, Furosemide dose escalation.

What condition does NCT00904488 study?

NCT00904488 studies Acute Decompensated Heart Failure.

Is NCT00904488 still recruiting?

NCT00904488 is currently terminated. Last updated 13 February 2018.

Are results published for NCT00904488?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-02-13 · How we verify

NCT00904488

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Addition of Oral Metolazone to Intermittent Intravenous Furosemide Versus Transition to Continuous Infusion Furosemide in Acute Decompensated Heart Failure Patients Experiencing an Inadequate Response to Therapy

Terminated Phase 4 Results posted Last updated 13 February 2018

What this trial tests

Phase 4 trial testing Addition of oral Metolazone in Acute Decompensated Heart Failure in 11 participants. Terminated before completion.

Timeline

1 October 2008

Primary endpoint
28 May 2016

14 November 2017

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 October 2008
Primary completion	28 May 2016
Estimated completion	14 November 2017
Sites	1 location across United States

Drugs / interventions tested

Addition of oral Metolazone — full drug profile →
Furosemide dose escalation — full drug profile →

Conditions studied

Acute Decompensated Heart Failure — all drugs for Acute Decompensated Heart Failure →

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, any sex, with Acute Decompensated Heart Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)
Time frame: 24-48 hours
Net fluid output = fluid output during 24-48 hours after randomization - fluid intake during 24-48 hours after randomization. A negative value means that daily fluid intake was less than the daily fluid output.

Sponsor's own description

The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Continuous infusion versus bolus injection of loop diuretics for acute heart failure.
Rasoul D, Zhang J, Farnell E, Tsangarides AA, et al · · 2024 · cited 6× · PMID 38775253 · DOI 10.1002/14651858.cd014811.pub2
Efficacy and safety of combining a thiazide diuretic with a loop diuretic in decompensated heart failure: A systematic review and meta-analysis.
Bessa R, Martins OC, Mamede I, Franchini AEO, et al · · 2025 · PMID 40727111 · DOI 10.1016/j.ijcha.2025.101739

Verify or expand the search:

Other recruiting trials for Acute Decompensated Heart Failure

Currently open trials in the same condition.

NCT07372040 — Add-on Diuretics in Acute Decompensated Heart Failure · Phase 2 · recruiting
NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
NCT06556810 — IC14 for Treatment of Acute Decompensated Heart Failure · Phase 1, PHASE2 · active not recruiting
NCT06714409 — Venous Ultrasound Guided Organ Decongestion in Patients Hospitalized with Acute Decompensated Heart Failure · NA · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00904488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 13 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00904488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing